OPGEN, INC.
GAITHERSBURG, MD

Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute. Mr. Dec, has more than 20 years of public company financial leadership experience in technology and healthcare companies. He has served in chief financial officer or other senior financial executive roles at companies in a number of industries, including three publicly traded companies listed on NASDAQ or AMEX, such as Corvis Corporation, and at private equity-backed companies. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, He was Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. Mr. Dec also has public accounting firm experience. He is an adjunct professor at Mount St. Mary’s University in Emmitsburg, Maryland, where he teaches M.B.A. courses in Finance. Mr. Sapiro joined OpGen in December, 2011 with responsibility for leading the development of the Company’s bioinformatics applications, software, databases and information technology operations. Prior to OpGen, he was senior vice president at SAIC-Frederick overseeing the Information Systems Program for the National Cancer Institute at Frederick with responsibility for information technology, scientific computing and bioinformatics. Among his projects were technical program management and operations for the cancer Biomedical Informatics Grid (caBIG™), the cancer Human Biobank (caHUB) and The Cancer Genome Atlas (TCGA). Prior to SAIC, Mr. Sapiro was vice president for information technology with the J. Craig Venter Institute. He is active in the regional and national technology and research communities, having served on many life sciences and biotech focused advisory boards and review committees. Mr. Farmer joined OpGen in 2012 and is responsible for all global commercial activities related to the FDA-cleared, IVD products and CLIA-certified clinical laboratory services. He has 25 years of experience in the biotechnology and IVD industries, most of which focused on the commercialization of molecular diagnostic technologies, including world-wide product launches. Prior to OpGen, he held various marketing and strategic leadership positions at Qiagen, Becton Dickinson, Digene, and Life Technologies/Invitrogen (now Thermo Fisher Scientific). Additionally, he is an adjunct professor at Johns Hopkins University where he teaches courses in Marketing. Mr. Farmer holds a B.S. in Biology from Virginia Commonwealth University, and an M.B.A from Carey Business School, Johns Hopkins University. Mr. Guiel is responsible for FDA-cleared, IVD product manufacturing, CLIA-certified clinical laboratory services, quality assurance and regulatory affairs, as well as, logistics for both the Gaithersburg, MD and Woburn, MA sites. He has more than 30 years of industry experience within the biotechnology industry, managing product and service operations. Before joining OpGen, he was the COO at OncoPlex Diagnostics where he established a CLIA-certified laboratory to identify and quantitate specific drug-target proteins in FFPE oncology specimens employing a multiplexed SRM mass spectrometry assay. Mr. Guiel was at Life Technologies/Invitrogen (now Thermo Fisher Scientific) for 18 years. There, he was responsible for establishing global ordering and distribution, manufacturing operations, and partnerships in Japan, New Zealand, Brazil, the U.K. and throughout the U.S. Dr. Walker’s responsibilities include leading the development of genomic technologies and new products supporting molecular diagnostics for infectious diseases. Prior to OpGen, He previously led drug target validation, biomarker discovery and clinical diagnostic development at Pfizer, GlaxoSmithKline (GSK), Becton Dickinson (BD), Duke University and The Biomarker Factory across most disease areas and stages of development from discovery through late clinical trials. Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute. Mr. D’Andrea is managing general partner of Valhalla Partners, a venture capital firm, a position he has held since January 2012. He previously served as administrative general partner of Valhalla Partners since June 2002, and was a co-founder of Valhalla Partners in 2002. From June 1999 to February 2002, Mr. D’Andrea was Chief Financial Officer of Advanced Switching Communications, Inc., a Nasdaq-listed company that completed its IPO in October 2000. Prior thereto from 1989 to 1999 he held senior financial positions with a number of privately held and public companies. Mr. D’Andrea is currently a director of four privately held companies and has served on the boards of two publicly traded companies in the past. Dr. Harris is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas. He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly. Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys. He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.